Table 1 Formulation composition and the responses of clozapine transdermal patches using design-expert software.

From: Formulation development and evaluation, in silico PBPK modeling and in vivo pharmacodynamic studies of clozapine matrix type transdermal patches

Batch

Eudragit

PEG

Oleic acid

Tensile strength

Flux

Y3

(mg)

(%)

(%)

(Kg/cm2)

(µg/cm2/h)

Q24

(X1)

(X2)

X3

(Y1)

(Y2)

(%)

F1

50

10

1

1.025

136.292

102.763

F2

125

15

1.500

1.027

142.668

98.659

F3

200

20

1

1.057

134.198

70.141

F4

50

20

2

1.330

166.605

103.651

F5

125

23.408

1.500

1.392

151.074

97.427

F6

125

15

2.340

1.042

182.049

99.653

F7

50

20

1

1.217

134.860

98.653

F8

125

15

1.500

1.055

145.557

95.987

F9

251.134

15

1.500

1.170

153.814

55.984

F10

125

15

1.500

1.047

149.907

99.915

F11

200

10

1

0.990

140.943

69.433

F12

125

15

1.500

1.037

142.419

97.172

F13

125

15

1.500

1.052

148.542

98.564

F14

50

10

2

0.955

171.911

100.943

F15

200

20

2

1.095

163.289

71.561

F16

125

6.591

1.500

0.987

141.818

96.949

F17

125

15

1.500

1.045

149.476

98.893

F18

125

15

0.659

1.027

124.909

97.876

F19

200

10

2

0.962

147.101

70.540

Back to article page